Three quarters of guideline panellists have ties to the drug industryBMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f4998 (Published 14 August 2013) Cite this as: BMJ 2013;347:f4998
- Ingrid Torjesen
The majority of health professionals in the United States who sit on guideline panels deciding the definitions or diagnostic criteria for common conditions have financial ties to pharmaceutical and medical device companies, a study has found.1
The researchers identified 16 publications by national and international guideline panels that had been published between 2000 and 2013 on the diagnosis of 14 common conditions. Of these, 10 proposed changes widening diagnostic definitions, one narrowing definitions, and the impact of the other five was unclear.
Conditions that had their definitions expanded included high blood pressure, Alzheimer’s disease, and rheumatoid arthritis. Panels widened definitions …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial